CROPIN
11.6.2019 10:27:05 CEST | Business Wire | Press release
CropIn, a full-stack agri-tech organization, has registered a 3X ARR growth over the last five quarters and has grown by 325% during the last 15 months. The SaaS provider, which first marked its global presence in late 2017, is today generating more than 60% of its current revenue from its international markets and is targeting to achieve 70% of the revenue from these markets in the next one year. CropIn has partnered with over 100+ B2B enterprise clients across 30+ countries in Asia, Europe, Africa, and the Americas, enriching the lives of over 2.1 million farmers by digitizing over 5 million acres of farmland.
A pioneer in the agri-tech space, the company's growth story started with the launch of its first product ‘SmartFarm ’. SmartFarm is a comprehensive digital farming technology that enables efficient farm management through digitization, empowers data-driven decision-making, and provides complete visibility of people, processes, and performance on the field.
‘SmartFarm ’ is a globally recognized and awarded digital platform, which was recently named the ‘Best Innovation in Digital Farming Technology’ at Agrow Awards in London. (SmartFarm case study link on HBR )
CropIn launched its predictive and prescriptive solution, ‘SmartRisk™ ’ that leverages Satellite Imagery, Artificial Intelligence and Machine Learning. SmartRisk™ is a next generation solution that can detect crops remotely, predict crop health and estimate yield ahead of the harvest, and provides valuable insights for the agri industry, financial institutions, growers and policy makers.
SmartRisk™ is capable of performing regional/plot level analysis, on a 10x10 sq mt pixel that is updated every 10 days, consolidating it at a village, postal code, district and country view. It is the perfect product for business entities such as input companies, commodity traders, farming companies, banks, and insurance companies that are seeking regional insights to make major financial and strategic decisions. CropIn has carried out swift and successful technology implementations in the agri-tech space on a global scale. The company’s other core product offerings include SmartSales, mWarehouse and Acresquare.
CropIn has raised $12 million funding till date, including Series A funding from BEENEXT, and $8 million in a Series B funding from the Bill and Melinda Gates Foundation Strategic Investment Fund (London & Seattle) and Chiratae Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005394/en/
Contact:
Team Pumpkin Roshan Ravindra roshan@teampumpkin.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 08:30:00 CEST | Press release
The launch brings rhode into physical retail across Europe, previously only being available for purchase in the region through rhodeskin.com rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 07:00:00 CEST | Press release
New three-year ARCADIA long-term extension data demonstrate that Nemluviois well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1 The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least 75% improvement in eczema severity, up to 67% achieved near-complete skin clearance, and approximately 90% reported clinically meaningful improvements in itch and quality of life at Week 1521 Additional analyses to be presented further establish itch and skin lesions as central drivers of sleep disturbance and overall quality of life impairment in prurigo nodularis and atopic dermatitis2,3 Collectively, these data reinforce our understanding of the long-term efficacy and safety profile of Nemluvio and underscore Galderma's long-standing commitment to improving the outcomes that matter most to patients with atopic dermatiti
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill30.9.2026 07:00:00 CEST | Press release
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib Additional analyses from the pivotal LATITUDE PsO 3001 and 3002 studies showed durable skin clearance and rapid and continued improvements in patient-reported itch and quality of life Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis.1 Presented during late-breaking and oral sessions at the European Academy of Dermatology & Venereology (EADV) Congress 2026, these results demonstrate zaso
Ant International’s Antom Supports Google Gemini in Expanding Access to AI Service in Asia30.9.2026 06:16:00 CEST | Press release
The partnership was first launched in Indonesia, reaching about 10 million users, with plans to expand to more markets. Antom consolidates billing, tax, risk management, marketing and account services, covering the subscription lifecycle for AI companies. Google Gemini and Antom, a leading merchant payment and digitisation services provider under Ant International, today announced a strategic partnership to make AI tools for learning, creativity and productivity more accessible to users in Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929520038/en/ Google AI Plus free trial offers are available in select digital payment and retail channels partnering with A+Rewards in Indonesia, with more markets to follow. Promoting Google AI Plus through AI-powered growth engine The collaboration will leverage A+Rewards, Antom’s digital marketing solution powered by privacy-preserving computing and AI technologies, and its extens
Signaloid Joins CERN openlab's Heterogeneous Architectures Testbed to Explore the Future of Scientific Computing30.9.2026 06:00:00 CEST | Press release
British deep-tech company Signaloid joins CERN openlab as an Industrial Member, contributing its probabilistic computing technology to the CERN openlab Heterogeneous Architectures Testbed.CERN and Signaloid will jointly evaluate whether Signaloid's UxHw® technology can accelerate Monte Carlo event generation for the High-Luminosity Large Hadron Collider.The collaboration reflects a broader shift towards heterogeneous computing architectures designed to meet the growing demands of next-generation scientific computing. British computing company Signaloid has joined CERN openlab, the public-private partnership through which CERN evaluates emerging information technologies for scientific computing. As part of the collaboration, CERN and Signaloid will evaluate Signaloid's distribution-extended compute hardware (UxHw®) technology within the CERN openlab Heterogeneous Architectures Testbed, which explores new processor technologies for future scientific computing infrastructures. This press
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom